Operating
D&A
Alnylam Pharmaceuticals D&A increased by 0.3% to $13.55M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.9%, from $14.41M to $13.55M. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 4.0% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Higher levels typically reflect significant historical capital expenditures or acquisitions that are now being expensed over time.
Detailed definition
This metric represents the non-cash accounting charges used to allocate the cost of tangible assets and intangible asset...
Peer comparison
Capital-intensive hardware manufacturers generally show higher D&A relative to revenue than pure-play software companies.
Metric ID:
depreciation_and_amortization_cfHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.81M | $11.79M | $11.38M | $9.46M | $10.10M | $10.60M | $14.31M | $14.07M | $13.18M | $13.33M | $13.48M | $13.52M | $15.00M | $13.98M | $14.17M | $14.41M | $13.94M | $13.80M | $13.51M | $13.55M |
| QoQ Change | — | -0.2% | -3.5% | -16.8% | +6.7% | +5.0% | +35.0% | -1.7% | -6.3% | +1.1% | +1.2% | +0.3% | +11.0% | -6.8% | +1.3% | +1.7% | -3.2% | -1.0% | -2.2% | +0.3% |
| YoY Change | — | — | — | — | -14.5% | -10.1% | +25.8% | +48.7% | +30.5% | +25.7% | -5.8% | -3.9% | +13.8% | +4.9% | +5.1% | +6.6% | -7.1% | -1.3% | -4.7% | -5.9% |
Range$9.46M – $15.00M
CAGR+2.9%
Avg YoY Growth+6.8%
Median YoY Growth+1.8%
D&A at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's d&a?
- Alnylam Pharmaceuticals (ALNY) reported d&a of $13.55M in Q1 2026.
- How has Alnylam Pharmaceuticals's d&a changed year-over-year?
- Alnylam Pharmaceuticals's d&a decreased by 5.9% year-over-year, from $14.41M to $13.55M.
- What is the long-term trend for Alnylam Pharmaceuticals's d&a?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's d&a has grown at a 4.0% compound annual growth rate (CAGR), from $47.57M to $55.66M.
- What does d&a mean?
- The accounting process of spreading the cost of physical and intangible assets over time.